Skip to main content

Table 5 Comparison between survivors and non-survivors at 6 months

From: Prognostic implications of IDH1rs11554137 and IDH2R140Q SNPs mutations in cytogenetically normal acute myeloid leukemia

   Survivors
(N = 33, 41.3%)
Died
(N = 47, 58.7%)
p value*#
Age (years) Mean ± SD 38.8 ± 10.7 49.2 ± 17.7 0.004
Gender N (%)    0.077
 Male   24 (72.7) 25 (53.2)  
 Female   9 (27.3) 22 (46.8)  
Hepatomegaly N (%)    0.429
 Negative   16 (48.5) 27 (57.4)  
 Positive   17 (51.5) 20 (42.6)  
Splenomegaly N (%)    
 Negative   12 (36.4) 17 (36.2) 1.000
 Positive   21 (63.6) 30 (63.8)  
Lymphadenopathy N (%)    0.537
 Negative   21 (63.6) 33 (70.2)  
 Positive   12 (36.4) 14 (29.8)  
Hemoglobin (g/dl) Mean ± SD 6.3 ± 2.5 7.1 ± 1.6 0.085
TLC (× 109/L) Mean ± SD 72.4. ± 34.5 66.6 ± 46.5 0.545
Platelets (× 109/L) Mean ± SD 24.2 ± 9.5 33.5 ± 20.1 0.016
Blast cells (%) Mean ± SD 65.4 ± 17.8 76.9 ± 13.6 0.002
FAB classification N (%)    0.082
 M1   3 (9.1) 9 (19.1)  
 M2   16 (48.5) 28 (59.6)  
 M4   12 (36.4) 6 (12.8)  
 M5   2 (6.1) 4 (8.5)  
IDH1SNPrs11554137 N (%)    0.003
 Normal   33 (100) 36 (76.6)  
 Heterozygous   0 (0) 11 (23.4)  
IDH2R140Q N (%)    0.146
 Normal   30 (91.3) 37 (78.7)  
 Heterozygous   3 (9.1) 10 (21.3)  
  1. N number, SD standard deviation, TLC total leucocytic count, IQR interquartile range
  2. *Unpaired t test for quantitative data with parametric distribution
  3. #Chi-square test for qualitative data
  4. Fisher’s exact test when the expected count in any cell was found at less than 5
  5. A p value <0.05 was considered the cut-off value for significance in all analyses